Affiliation:
1. Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine Brigham and Women's Hospital Boston Massachusetts USA
2. Division of Endocrinology, Diabetes and Metabolism, Northwell Health Manhasset New York USA
3. Division of Breast Oncology, Department of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts USA
Abstract
AbstractAimsIn patients with breast cancer (BCa) and diabetes (DM), diabetes distress (DD) and treatment satisfaction (DTS) can influence BCa management and outcomes. We assessed the impact of implementing a personalized diabetes care model in patients with BCa.MethodsPatients in active treatment or surveillance for BCa with an HbA1c > 53 mmol/mol (7%) or random blood glucose >11.1 mmol/L were included. Participants were offered continuous glucose monitoring (CGM), virtual care and a dedicated diabetes provider for 6 months. Primary outcomes included DD measured by the Diabetes Distress Survey (DDS) and DTS measured by the Diabetes Treatment Satisfaction Questionnaire (DTSQ). Questionnaires were conducted at 0, 3 and 6 months.ResultsThirty‐one women were enrolled (median age 61, IQR 49.0–69.0). Compared to baseline, the mean DDS score was lower at both 3 months (2.2 vs. 1.8 [n = 27], p = 0.004, SD = 0.70) and 6 months (2.3 vs. 1.8 [n = 23], p = 0.002, SD = 0.70). The mean DTSQ score was higher at 3 months (baseline: 20.5 vs. 3 months: 28.7 [n = 28], p < 0.001, SD = 9.2) and 6 months (baseline: 20.4 vs. 6 months: 30.0 [n = 26], p < 0.001, SD = 9.7).ConclusionsPersonalized diabetes care models that emphasize remote management and optimize access for those with BCa may lower DD and improve DTS.
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine